Nuwellis Inc (NUWE)

Currency in USD
5.100
-0.110(-2.11%)
Real-time Data·
NUWE Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
NUWE is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
5.0905.250
52 wk Range
4.820175.980
Key Statistics
Prev. Close
5.21
Open
5.09
Day's Range
5.09-5.25
52 wk Range
4.82-175.98
Volume
22.91K
Average Volume (3m)
1M
1-Year Change
-95.23%
Book Value / Share
34.36
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NUWE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

Nuwellis Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Nuwellis Inc Company Profile

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through specialty healthcare distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Indonesia, Israel, Italy, Panama, Romania, Singapore, Slovak Republic, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

Nuwellis Inc Earnings Call Summary for Q1/2025

  • Revenue up 3% YoY to $1.9M in Q1 2025; net loss of $3M ($0.69/share); stock stable despite 89% decline over past year
  • Gross margin decreased to 56% from 64.1%; operating expenses reduced by 31%; $2.6M cash reserves with no outstanding debt
  • Critical care sales expected to stabilize; outpatient clinic revenue growth anticipated Q2-Q4 2025
  • REVERSE HF trial enrollment continues; Vivian trial to start late 2025/early 2026; analyst consensus: hold, 24% revenue growth forecast
  • CEO highlights strategic inflection point; CFO emphasizes disciplined expense management amid market challenges
Last Updated: 13/05/2025, 14:36
Read Full Transcript

Compare NUWE to Peers and Sector

Metrics to compare
NUWE
Peers
Sector
Relationship
P/E Ratio
−0.1x−3.5x−0.5x
PEG Ratio
-−0.190.00
Price/Book
0.2x2.8x2.6x
Price / LTM Sales
0.1x2.8x3.3x
Upside (Analyst Target)
-44.9%42.8%
Fair Value Upside
Unlock3.4%6.5%Unlock

Earnings

Latest Release
May 13, 2025
EPS / Forecast
-0.69 / -0.41
Revenue / Forecast
1.90M / 3.86M
EPS Revisions
Last 90 days

NUWE Income Statement

People Also Watch

32.79
BMNR
-1.53%
0.92
KLTO
-6.04%
0.040
NCNA
-5.65%
14.0700
INKT
-3.17%
16.12
SRPT
-3.76%

FAQ

What Stock Exchange Does Nuwellis Trade On?

Nuwellis is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Nuwellis?

The stock symbol for Nuwellis is "NUWE."

What Is the Nuwellis Market Cap?

As of today, Nuwellis market cap is 595.30K.

What Is Nuwellis's Earnings Per Share (TTM)?

The Nuwellis EPS (TTM) is -174.09.

From a Technical Analysis Perspective, Is NUWE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Nuwellis Stock Split?

Nuwellis has split 11 times.

How Many Employees Does Nuwellis Have?

Nuwellis has 38 employees.

What is the current trading status of Nuwellis (NUWE)?

As of 06 Aug 2025, Nuwellis (NUWE) is trading at a price of 5.10, with a previous close of 5.21. The stock has fluctuated within a day range of 5.09 to 5.25, while its 52-week range spans from 4.82 to 175.98.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.